Global Transcatheter Mitral Valve Replacement (TMVR) Market Growth (Status and Outlook) 2023-2029

Global Transcatheter Mitral Valve Replacement (TMVR) Market Growth (Status and Outlook) 2023-2029

TMVR, also known as transcatheter mitral valve replacement is a way of replacing the mitral valve in the heart without the need for conventional open-heart surgery. TMVR transcatheter mitral valve replacement is a treatment for mitral valve stenosis (tight mitral valve) or mitral valve regurgitation (leaky mitral valve) or a mix of the two. TMVR transcatheter mitral valve replacement was developed initially as a method of replacing the mitral valve in patients considered too high risk for surgery but will likely replace mitral valve replacement surgery in the future as the technology improves and the outcomes are proved.
LPI (LP Information)' newest research report, the “Transcatheter Mitral Valve Replacement (TMVR) Industry Forecast” looks at past sales and reviews total world Transcatheter Mitral Valve Replacement (TMVR) sales in 2022, providing a comprehensive analysis by region and market sector of projected Transcatheter Mitral Valve Replacement (TMVR) sales for 2023 through 2029. With Transcatheter Mitral Valve Replacement (TMVR) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transcatheter Mitral Valve Replacement (TMVR) industry.
This Insight Report provides a comprehensive analysis of the global Transcatheter Mitral Valve Replacement (TMVR) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transcatheter Mitral Valve Replacement (TMVR) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transcatheter Mitral Valve Replacement (TMVR) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transcatheter Mitral Valve Replacement (TMVR) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transcatheter Mitral Valve Replacement (TMVR).
The global Transcatheter Mitral Valve Replacement (TMVR) market size is projected to grow from US$ 1132.3 million in 2022 to US$ 6635.2 million in 2029; it is expected to grow at a CAGR of 28.7% from 2023 to 2029.
The classification of Transcatheter Mitral Valve Replacement (TMVR) includes MitraClip, Edwards PASCAL and Edwards SAPIEN 3. The market share of MitraClip in 2019 reached up to over 96%.
United States and Europe are the largest consumption place, with a revenue market share nearly 96% in 2019. The rest of global market mostly was taken up by China and Japan, which totally occupied a market share of over 2%.
This report presents a comprehensive overview, market shares, and growth opportunities of Transcatheter Mitral Valve Replacement (TMVR) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
MitraClip
Edwards PASCAL
Edwards SAPIEN 3
Segmentation by application
Functional Mitral Regurgitation (FMR)
Degenerative Mitral Regurgitation (DMR)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Edwards Lifesciences
Medtronic
Boston Scientific
Micro Interventional Devices
Neovasc
LivaNova
HighLife SAS

Please note: The report will take approximately 2 business days to prepare and deliver.